<http://schema.org/description>
"Merck has turned to Januvia and Janumet to lead its product lineup, but with new competition and worrying safety data, investors may want to reconsider the franchise&amp;#39;s growth prospects."^^<http://www.w3.org/2001/XMLSchema#string>
<http://www.fool.com/investing/general/2013/03/26/is-mercks-type-2-diabetes-blockbuster-in-trouble.aspx>